A Phase 2 Study of the Dual SYK/JAK Inhibitor Cerdulatinib Demonstrates Good Tolerability and Clinical Response in Relapsed/Refractory Peripheral T-Cell Lymphoma and Cutaneous T-Cell Lymphoma
Year: 2019
Type: conference-abstract
Source: Blood
Authors: Steven M. Horwitz, Tatyana A. Feldman, Brian T. Hess, Michael S. Khodadoust, Youn H. Kim, Javier Munoz, Manish R. Patel, Tycel J. Phillips, Stephen D. Smith, Sonali M. Smith, Ryan A. Wilcox, Matt R. Birrell, Janet M. Leeds, Pamela B. Conley, Glenn C. Michelson, Gregory P. Coffey, John T. Curnutte, Paul A. Hamlin
Institutions: Memorial Sloan Kettering Cancer Center, Hackensack University Medical Center, Medical University of South Carolina, MUSC Hollings Cancer Center, Stanford Medicine, Banner MD Anderson Cancer Center, Sarah Cannon, Florida Cancer Specialists & Research Institute, U-M Rogel Cancer Center, Seattle Cancer Care Alliance, University of Washington, University of Chicago, Fred Hutch Cancer Center, Portola Pharmaceuticals (United States)
Language: English
Subfield: Dermatology
Field: Medicine
Domain: Health Sciences
Open Access status: closed
OpenAlex ID: W2991319424